Wedbush Reiterates Outperform on Jade Biosciences, Maintains $47 Price Target
10/1/2026
Impact: 65
Healthcare
Wedbush analyst Laura Chico has reiterated an 'Outperform' rating on Jade Biosciences (NASDAQ: JBIO) and has maintained a price target of $47 for the stock.
AI summary, not financial advice
Share: